Hemogenyx Pharmaceuticals plc is pleased to announce that it has been informed by the U.S. Federal Food and Drug Administration that it has lifted the clinical hold on the Investigational New Drug application for HEMO-CAR-T for the treatment of acute myeloid leukemia.
